Simply put, investors are happy to see the company's pipeline move in the right direction following years of malaise. While many programs remain in the earliest stages of development, ArQule's bet on targeted treatments for cancers and rare diseases appears to be paying off. As of 12:05 p.m. EDT, the stock had settled to a 15.9% gain.